Table 2 Development of qualitative results for a) negative samples and samples containing other human corona viruses and b) a high viral load of either 4.75 × 106 copies/mL or 1.42 × 107 copies/mL for lateral flow tests and automated immunoassays.
From: Results of German external quality assessment schemes for SARS-CoV-2 antigen detection
(a) | Rapid Tests | Automated Immunoassays | |||||||
|---|---|---|---|---|---|---|---|---|---|
EQA term | Sample | Sample property | negative | positive | % negative results | negative | borderline | positive | % negative results |
2021 March | 410002 | negative control cells (MRC-5) | 265 | 1 | 99.6 | 62 | 0 | 0 | 100 |
2021 March | 410003 | HCoV 229E | 264 | 2 | 99.3 | 62 | 0 | 0 | 100 |
2021 June | 410008 | negative control cells (MRC-5) | 153 | 0 | 100 | 32 | 0 | 0 | 100 |
2021 June | 410010 | HCoV NL63 | 149 | 2 | 98.7 | 32 | 0 | 0 | 100 |
2021 September | 410011 | negative control cells (MRC-5) | 159 | 0 | 100 | 38 | 0 | 0 | 100 |
(b) | Rapid Tests | Automated Immunoassays | |||||||
|---|---|---|---|---|---|---|---|---|---|
EQA term | Sample | Sample property | negative | positive | % positive results | negative | borderline | positive | % positive results |
2021 March | 410004 | non-VOC 1.65 × 107 copies/mL | 5 | 262 | 98.1 | 0 | 0 | 62 | 100 |
2021 June | 410006 | 3 | 150 | 98.0 | 0 | 0 | 32 | 100 | |
410009 | 2 | 151 | 98.7 | 0 | 0 | 32 | 100 | ||
2021 September | 410012 | 4 | 155 | 97.5 | 0 | 0 | 38 | 100 | |
2021 September | 410013 | non-VOC 4.75 × 106 copies/mL | 9 | 150 | 94.3 | 1 | 0 | 37 | 97.4 |
2021 March | 410001 | non-VOC 1.60 × 106 copies/mL | 91 | 175 | 65.8 | 6 | 3 | 53 | 85.5 |
2021 June | 410007 | 71 | 82 | 53.6 | 4 | 3 | 25 | 78.1 | |
2021 September | 410014 | 71 | 88 | 55.3 | 11 | 1 | 26 | 68.4 | |
2021 March | 410005 | non-VOC 1.55 × 105 copies/mL | 250 | 16 | 6.0 | 51 | 2 | 9 | 14.5 |
2021 September | 410015 | Delta VOC 1.42 × 107 copies/mL | 6 | 153 | 96.2 | 0 | 1 | 37 | 97.4 |
